Nima Rezaei - Cancer Immunology: A Translational Medicine Context

This Springer imprint is published by the registered company Springer Nature Switzerland AG

The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

The rapid flow of studies in the field of cancer immunology during the last decade has increased our understanding of the interactions between the immune system and cancerous cells. In particular, it is now well-known that such interactions result in the induction of epigenetic changes in cancerous cells and the selection of less immunogenic clones as well as alterations in immune responses. Understanding the cross-talk between nascent transformed cells and cells of the immune system has led to the development of combinatorial immunotherapeutic strategies to combat cancer.

Cancer Immunologyseries, a three-volume book series, is intended as an up-to-date, clinically relevant review of cancer immunology and immunotherapy. The first edition of the book was published 4 years ago, which was very welcomed by the readers, made us to work on the second edition of the book in such a short period of time.

Volume I,Cancer Immunology: A Translational Medicine Context,is focused on the immunopathology of cancers. Volume II,Cancer Immunology: Bench to Bedside Immunotherapy of Cancers,is a translation text explaining novel approaches in the immunotherapy of cancers; and finally, Volume III,Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors,thoroughly addresses the immunopathology and immunotherapy of organ-specific cancers.

In Volume I, interactions between cancerous cells and various components of the innate and adaptive immune system are fully described. Notably, the principal focus is very much on clinical aspects, the aim being to educate clinicians on the clinical implications of the most recent findings and novel developments in the field. To meet this purpose, this volume was extended from 26 chapters in the first edition to 33 chapters in the second edition. After an overview on cancer immunology in Chap.. Finally, by allocating the final chapter to flow cytometry in cancer immunotherapy, Volume I comes to its end.

TheCancer Immunologyseries is the result of valuable contribution of more than 300 scientists from more than 100 well-known universities/institutes worldwide. I would like to hereby acknowledge the expertise of all contributors, for generously devoting their time and considerable effort in preparing their respective chapters. I would also like to express my gratitude to the Springer Nature publication for providing me the opportunity to publish the book.

Finally, I hope that this translational book will be comprehensible, cogent, and of special value for researchers and clinicians who wish to extend their knowledge on cancer immunology.

I would like to express my gratitude to the editorial assistants of this book, Dr. Farnaz Delavari and Dr. Mahsa Keshavarz-Fathi. With no doubt, the book would not have been completed without their contribution.